Don’t miss 
the data.

Explore renal denervation at TCT.

Don’t miss these five renal denervation sessions at TCT 2021.

Topics include clinical evidence, patient preference, and more.

WEDNESDAY OCT. 27, 10 AM EDT

Durability of Radiofrequency Catheter-based Renal Denervation Associated With Lack of Functional Nerve Recovery at 6 Months in Normotensive Swine Model

Prof. Andrew Sharp

Free to all via TCT Connect

Add to calendar MM/DD/YYYY 10/27/2021 10:00 AM 10/27/2021 11:00 AM America/New_York Durability of Radiofrequency Catheter-based Renal Denervation Associated With Lack of Functional Nerve Recovery at 6 Months in Normotensive Swine Model

Prof. Andrew Sharp discusses the science of renal denervation, including long-term durability data.

 TCT World Connect 0 TRANSPARENT

THURSDAY NOV. 4, 4:10 PM EDT

Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension

Dr. Michael Weber

For registered attendees (physical and virtual)

Add to calendar MM/DD/YYYY 11/04/2021 04:10 PM 11/04/2021 04:17 PM America/New_York Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension

Dr. Michael Weber presents findings from the US Patient Preference (PPI) research.

 TCT 2021: Innovation Theater, Halls A-B, Level I 0 TRANSPARENT

THURSDAY NOV. 4, 4:47 PM EDT

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Breaking Evidence and Next Step

Dr. David Kandzari

For registered attendees (physical and virtual)

Add to calendar MM/DD/YYYY 11/04/2021 04:47 PM 11/04/2021 04:59 PM America/New_York The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Breaking Evidence and Next Step

For registered attendees (physical and virtual). Dr. Kandzari shares updates on the SPYRAL Clinical Trial Program.

 TCT 2021: Innovation Theater, Halls A-B, Level I 0 TRANSPARENT

FRIDAY NOV. 5, 2 PM EDT

Transforming Hypertension Treatment: Updates on the Medtronic SPYRAL HTN Global Clinical Trial Program

Featuring Prof. Michael Böhm, Prof. Flavio Ribichini, Prof. Andrew Sharp, and Dr. Raymond Townsend

Moderated by Prof. Felix Mahfoud

Free to all via TCT Connect

Add to calendar MM/DD/YYYY 11/05/2021 02:00 PM 11/05/2021 03:00 PM America/New_York Transforming Hypertension: Updates on the Medtronic SPYRAL HTN Global Clinical Trial Program

Free to all via TCT Connect. Featuring Prof. Michael Böhm, Prof. Flavio Ribichini, Prof. Andrew Sharp, and Dr. Raymond Townsend. Moderated by Prof. Felix Mahfoud. Program updates, including the latest data.

 TCT 2021: World Connect Studio, Halls A-B, Level I 0 TRANSPARENT

SATURDAY NOV. 6, 6:30 AM EDT

Transforming Hypertension Treatment: From Evidence to Consensus to Action

Featuring Dr. Raymond Townsend, Prof. Atul Pathak, Prof. Konstantinos Tsioufis, Dr. Eric Secemsky, and Prof. Joachim Weil

For registered attendees (physical and virtual)

Add to calendar MM/DD/YYYY 11/06/2021 06:30 AM 11/06/2021 07:30 AM America/New_York Transforming Hypertension: From Evidence to Consensus to Action

For registered attendees (physical and virtual). Featuring Dr. Raymond Townsend, Prof. Atul Pathak, Prof. Konstantinos Tsioufis, Dr. Eric Secemsky, and Prof. Joachim Weil. A discussion of renal denervation, including US patient preference data, a recent consensus statement, and patient selection.

 TCT 2021: Innovation Theater, Halls A-B, Level I 0 TRANSPARENT

Sign up to be notified when new Medtronic renal denervation data becomes available.

Get data first
The Medtronic Symplicity Spyral™ Renal Denervation Catheter held by a gloved hand.

Caution: Investigational device. Limited by U.S. law to investigational use.

About the clinical program

The SPYRAL HTN Clinical Program is evaluating the Symplicity Spyral™ Renal Denervation system, an investigational device, for hypertension.

The program purpose is to provide information about the safety and effectiveness of an investigational procedure to help reduce blood pressure in patients whose blood pressure is uncontrolled.

Medtronic is committed to addressing unmet hypertension needs. More than 4,000 patients have been studied across multiple trials.1–6

Explore the program

Caution: Investigational device. Limited by U.S. law to investigational use.

A hypertension patient in illustrated form.

Take action on hypertension

Clinical trials are now enrolling. If you have patients with hypertension, encourage them to visit our patient education site at www.hbpstudy.com where they can find out if they qualify for an upcoming trial.

Visit site

Caution: Investigational device. Limited by U.S. law to investigational use.

1

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391:2346–2355.

2

Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017;390(10108):2160–2170. 

3

Symplicity HTN-1 Investigators. Hypertension Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension-Durability of Blood Pressure Reduction Out to 24 Months. Hypertension. 2011;57:911-917.

4

Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet. 010;376:1903-1909.

5

Bhatt DL, Kandzari DE, O'Neill WW. A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine. 2014;370:1393–1401. 

6

Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; Published online March 29, 2020. DOI: 10.1016/S0140-6736(20)30554-7.